CoChat

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

Open access
Sacks, Frank M., Pfeffer, Marc A., Moye, Lemuel A., Rouleau, Jean L., Rutherford, John D., Cole, Thomas G., Brown, Lisa, Warnica, J. Wayne, Arnold, J. Malcolm O., Wun, Chuan-Chuan, Davis, Barry R., Braunwald, Eugene · 1996 · New England Journal of Medicine

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

BACKGROUND: In patients with high cholesterol levels, lowering the cholesterol level reduces the risk of coronary events, but the effect of lowering cholesterol levels in the majority of patients with coronary disease, who have average levels, is less clear. METHODS: In a double-blind trial lasting five years we administered either 40 mg of pravastatin per day or placebo to 4159 patients (3583 men and 576 women) with myocardial infarction who had plasma total cholesterol levels below 240 mg per deciliter (mean, 209) and low-density lipoprotein (LDL) cholesterol levels of 115 to 174 mg per deciliter (mean, 139). The primary end point was a fatal coronary event or a nonfatal myocardial infarction. RESULTS: The frequency of the primary end point was 10.2 percent in the pravastatin group and 13.2 percent in the placebo group, an absolute difference of 3 percentage points and a 24 percent reduction in risk (95 percent confidence interval, 9 to 36 percent; P = 0.003). Coronary bypass surgery was needed in 7.5 percent of the patients in the pravastatin group and 10 percent of those in the placebo group, a 26 percent reduction (P=0.005), and coronary angioplasty was needed in 8.3 percent of the pravastatin group and 10.5 percent of the placebo group, a 23 percent reduction (P=0.01). The frequency of stroke was reduced by 31 percent (P=0.03). There were no significant differences in overall mortality or mortality from noncardiovascular causes. Pravastatin lowered the rate of coronary events more among women than among men. The reduction in coronary events was also greater in patients with higher pretreatment levels of LDL cholesterol. CONCLUSIONS: These results demonstrate that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejm199610033351401

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Research works printed but not linked: 2

  1. 1994, Lancet, 344, 1383
  2. Ries LA, Miller BA, Hankey BF, Kosary CL, Haras A, Edwards BK, eds. SEER cancer statistics review, 1973-1991: tables and graphs. Bethesda, Md.: National Cancer Institute, 1994. (NIH publication no. 94-2789.)

Cited by

See all 7,439

Metadata

Authors
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., Davis, B. R., & Braunwald, E.
Affiliations
  • Brigham and Women's Hospital (US)
  • Université de Sherbrooke (CA)
  • The University of Texas Southwestern Medical Center (US)
  • Washington University in St. Louis (US)
  • Foothills Medical Centre (CA)
  • Victoria Hospital (CA)
Venue
New England Journal of Medicine
Published
1996-10-03
Volume
335
Issue
14
Pages
1001-1009
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2322095705
Cited by
7,439
References
33
Citations by year
2026: 22 · 2025: 23 · 2024: 62 · 2023: 57 · 2022: 55 · 2021: 79 · 2020: 94 · 2019: 86 · 2018: 97 · 2017: 105 · 2016: 122 · 2015: 129 · 2014: 164 · 2013: 189 · 2012: 188
FWCI
361.43
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
pravastatin, statins, myocardial infarction, coronary events, LDL cholesterol, cholesterol-lowering therapy, secondary prevention, coronary artery bypass grafting, coronary angioplasty, stroke, sex differences
MeSH terms
Adult, Aged, Anticholesteremic Agents, Coronary Artery Bypass, Cholesterol, Coronary Disease, Double-Blind Method, Female, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Recurrence, Angioplasty, Balloon, Coronary, Incidence, Survival Analysis, Treatment Outcome, Pravastatin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. https://app.cochat.ai/papers/10.1056/nejm199610033351401
The paper
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., Davis, B. R., & Braunwald, E. (1996). The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels. New England Journal of Medicine. https://doi.org/10.1056/nejm199610033351401

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.